bluebird bio to Split into Two Separate Companies
- Posted by ISPE Boston
- On January 14, 2021
bluebird bio has announced its intent to separate its severe genetic disease (SGD) and oncology businesses into differentiated and independent publicly traded companies. bluebird bio, Inc. will retain focus on SGD and will launch its oncology business (“Oncology Newco”) as a new entity. Upon completion of the separation, current chief bluebird, Nick Leschly, will lead Oncology […]
Read More